Stocktoria
SANGAMO THERAPEUTICS, INC SGMO
OTC · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-04-06
SANGAMO THERAPEUTICS, INC financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.6M | $57.8M | $176.2M | $111.3M | $110.7M | $118.2M | $102.4M | $84.5M | $36.6M | $19.4M |
| R&D expense | $112.7M | $111.5M | $234.1M | $249.9M | $230.8M | $180.6M | $145.9M | $114.9M | $65.7M | $65.6M |
| Operating income | -$121.2M | -$104.0M | -$274.0M | -$201.3M | -$183.3M | -$129.6M | -$105.2M | -$77.2M | -$56.4M | -$72.6M |
| Income tax | -$568,000 | -$167,000 | -$5.1M | $429,000 | $306,000 | $345,000 | $0 | $0 | $0 | -$14,000 |
| Net income | -$122.9M | -$97.9M | -$257.8M | -$192.3M | -$178.3M | -$121.0M | -$95.2M | -$68.3M | -$54.6M | -$71.7M |
| EPS (diluted) | $-0.44 | $-0.49 | $-1.48 | $-1.25 | $-1.23 | $-0.90 | $-0.85 | — | — | — |
| Operating cash flow | -$97.2M | -$67.1M | -$224.8M | -$223.6M | -$233.3M | $169.9M | -$144.4M | $36.5M | $11.2M | -$65.9M |
| Free cash flow | -$97.3M | -$67.4M | -$246.0M | -$243.8M | -$256.5M | $155.2M | -$165.1M | -$6.5M | $7.4M | -$66.6M |
| Cash & equivalents | $20.9M | $41.9M | $45.2M | $100.4M | $178.9M | $131.3M | $80.4M | $140.4M | $49.8M | $22.1M |
| Total assets | $59.7M | $101.6M | $165.3M | $562.5M | $721.9M | $938.5M | $637.5M | $590.4M | $286.7M | $157.9M |
| Total liabilities | $74.0M | $78.9M | $82.4M | $267.6M | $346.6M | $441.2M | $204.8M | $223.1M | $98.8M | $21.7M |
| Shareholders' equity | -$14.3M | $22.8M | $82.9M | $295.0M | $375.3M | $498.2M | $432.7M | $367.3M | $187.9M | $136.2M |
Growth · year-over-year · Revenue CAGR 8.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -31.6% | -67.2% | +58.3% | +0.5% | -6.3% | +15.4% | +21.3% | +131.0% | +88.6% | -51.0% |
| Free cash flow growth | — | — | — | — | -265.3% | — | — | -187.7% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001001233 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.